PMID- 38025916
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2287-3651 (Print)
IS  - 2287-366X (Electronic)
IS  - 2287-3651 (Linking)
VI  - 12
IP  - 4
DP  - 2023 Oct
TI  - Comparison of media for a human peripheral blood mononuclear cell-based in vitro 
      vaccine evaluation system.
PG  - 328-336
LID - 10.7774/cevr.2023.12.4.328 [doi]
AB  - PURPOSE: Human peripheral blood mononuclear cell (PBMC)-based in vitro systems 
      can be of great value in the development and assessment of vaccines but require 
      the right medium for optimal performance of the different cell types present. 
      Here, we compare three commonly used media for their capacity to support innate 
      and adaptive immune responses evoked in PBMCs by Toll-like receptor (TLR) ligands 
      and whole inactivated virus (WIV) influenza vaccine. MATERIALS AND METHODS: Human 
      PBMCs were cultured for different periods of time in Roswell Park Memorial 
      Institute (RPMI), Dulbecco's minimal essential medium (DMEM), or Iscove's 
      modified DMEM (IMDM) supplemented with 10% fetal calf serum. The viability of the 
      cells was monitored and their responses to TLR ligands and WIV were assessed. 
      RESULTS: With increasing days of incubation, the viability of PBMCs cultured in 
      RPMI or IMDM was slightly higher than that of cells cultured in DMEM. Upon 
      exposure of the PBMCs to TLR ligands and WIV, RPMI was superior to the other two 
      media in terms of supporting the expression of genes related to innate immunity, 
      such as the TLR adaptor protein gene MyD88 (myeloid differentiation factor 88), 
      the interferon (IFN)-stimulated genes MxA (myxovirus resistance protein 1) and 
      ISG56 (interferon-stimulated gene 56), and the leukocyte recruitment chemokine 
      gene MCP1 (monocyte chemoattractant protein-1). RPMI also performed best with 
      regard to the activation of antigen-presenting cells. As for adaptive immunity, 
      when stimulated with WIV, PBMCs cultured in RPMI or IMDM contained higher numbers 
      of IFNgamma-producing T cells and secreted more immunoglobulin G than PBMCs cultured 
      in DMEM. CONCLUSION: Taken together, among the different media assessed, RPMI was 
      identified as the optimal medium for a human PBMC-based in vitro vaccine 
      evaluation system.
CI  - (c) Korean Vaccine Society.
FAU - Gong, Shuran
AU  - Gong S
AUID- ORCID: 0009-0005-2430-9322
AD  - Department of Medical Microbiology & Infection Prevention, University Medical 
      Center Groningen, University of Groningen, Groningen, The Netherlands.
FAU - Fajar, Putri
AU  - Fajar P
AUID- ORCID: 0000-0002-7854-8776
AD  - Department of Medical Microbiology & Infection Prevention, University Medical 
      Center Groningen, University of Groningen, Groningen, The Netherlands.
FAU - De Vries-Idema, Jacqueline
AU  - De Vries-Idema J
AUID- ORCID: 0000-0002-5687-1994
AD  - Department of Medical Microbiology & Infection Prevention, University Medical 
      Center Groningen, University of Groningen, Groningen, The Netherlands.
FAU - Huckriede, Anke
AU  - Huckriede A
AUID- ORCID: 0000-0002-2646-5143
AD  - Department of Medical Microbiology & Infection Prevention, University Medical 
      Center Groningen, University of Groningen, Groningen, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20231031
PL  - Korea (South)
TA  - Clin Exp Vaccine Res
JT  - Clinical and experimental vaccine research
JID - 101592344
PMC - PMC10655156
OTO - NOTNLM
OT  - Culture media
OT  - In vitro
OT  - Influenza vaccines
OT  - Ligands
OT  - Peripheral blood mononuclear cells
OT  - Toll-like receptor
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2023/11/29 18:43
MHDA- 2023/11/29 18:44
PMCR- 2023/10/01
CRDT- 2023/11/29 16:40
PHST- 2023/08/14 00:00 [received]
PHST- 2023/10/14 00:00 [accepted]
PHST- 2023/11/29 18:44 [medline]
PHST- 2023/11/29 18:43 [pubmed]
PHST- 2023/11/29 16:40 [entrez]
PHST- 2023/10/01 00:00 [pmc-release]
AID - 10.7774/cevr.2023.12.4.328 [doi]
PST - ppublish
SO  - Clin Exp Vaccine Res. 2023 Oct;12(4):328-336. doi: 10.7774/cevr.2023.12.4.328. 
      Epub 2023 Oct 31.